Pharnext esPharnext is an advanced, clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

Biotechnology

Pharnext

Hugo Brugière

Melissa Israel

Vincent Serra

Kévin Scialom

Gilbert Wagener

Serguei Nabirotchkine, PhD

Manon Larrazet

Raj Thota

The Leadership Team at Pharnext oversees the strategic direction and operational execution of the company’s innovative biopharmaceutical initiatives. Comprising experts in medicine, science, manufacturing, and quality, the team is responsible for guiding the advancement of Pharnext's clinical programs, including PXT3003 and PXT864, while fostering the development of the PLEOTHERAPY™ drug discovery paradigm. Their collaborative efforts ensure the robust progression of research, regulatory compliance, and the optimization of product development to meet the needs of patients with complex diseases.

Leadership Team

Clinical Operations and Development

Leadership Team

About

Team members

Other teams at Pharnext

Clinical Operations and Development